PPARG and gastric cancer: Our study demonstrated that Banxia-Shengjiang drug pair is closely related to gastric cancer, regulating the expression of core target proteins PTGS2, MMP9, PPARG, MMP2, and CXCR4 through the RAS/MAPK/MMP signaling pathway and improving the immune function of patients with gastric cancer, thus exerting an anti-gastric cancer effect.